Avanos Bundle
How has Avanos sharpened its sales and marketing focus?
Avanos refocused after its 2018 spin-off to concentrate on clinically differentiated franchises—pain, digestive and respiratory—shifting toward value-based outcomes, targeted KOL engagement, and procurement-savvy contracting to drive recurring demand.
The 2024 Respiratory Health divestiture for roughly $110 million and selective GI and interventional pain M&A sharpened its go-to-market to higher-growth, higher-margin niches, emphasizing evidence-backed launches and protocol adoption.
What is Sales and Marketing Strategy of Avanos Company? Avanos sells via specialist medtech channels, focused KOL programs, value-based contracting, targeted clinical evidence, and distributor alignment; see Avanos Porter's Five Forces Analysis for competitive context.
How Does Avanos Reach Its Customers?
Avanos sells primarily via a B2B model to hospitals, ASCs and specialty clinics using a mix of direct sales teams and global distributors; digital ordering and EDI have grown since 2020, contributing a modest but rising single-digit share of orders.
Primary Sales Channels
Direct account teams and clinical specialists cover IDNs, GPOs and VA/DoD in North America and EMEA, supported by distribution partners for logistics and formulary access.
Distributor-Led Markets
In APAC and LATAM Avanos relies on in-country distributors for regulatory, tender and last-mile execution, especially for consumables and accessories.
Channel Mix by Portfolio
Interventional pain and digestive health skew direct due to clinical education needs; legacy respiratory SKUs had higher distributor mix before the 2024 divestiture.
GPO and IDN Contracts
By 2024 more than 70% of U.S. acute-care revenue was under GPO/IDN agreements, providing volume stability and disciplined pricing.
Channel evolution includes deeper ASC penetration and selective DTC-style education that routes patients to providers; exclusive system evaluations and conversions drive account lifts through kit and accessory pull-through.
Key Channel Facts and Tactics
Sales channels combine direct coverage, distributor networks and growing digital commerce to match product clinical needs and geography.
- Major distribution partners include Owens & Minor, Cardinal Health and Medline for logistics and formulary access
- E-commerce and integrated EDI account for a modest but growing single-digit percentage of orders since 2020
- ASCs grew mid- to high-single digits industry-wide in 2023–2024, a strategic focus for deeper penetration
- Conversion deals can lift account revenue by 10–20% in year one through kit, tube and accessory pull-through
For context on competitive positioning and channel implications see Competitors Landscape of Avanos for further analysis of Avanos sales strategy and go-to-market execution.
Avanos SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Marketing Tactics Does Avanos Use?
Avanos employs a clinically led marketing stack combining KOL-driven education, peer-reviewed evidence dissemination, procedure workshops, and in-hospital in-services with digital SEO, paid search, and specialty-targeted email nurturing to drive clinician adoption and trials.
Clinically Led Education
KOLs lead CME and peer-reviewed dissemination to build trust among anesthesiology, gastroenterology, and critical care clinicians.
Procedure-Focused SEO
SEO targets procedure keywords like 'genicular nerve RF ablation' and 'post-pyloric feeding placement' to capture clinician intent.
Digital Case Content
LinkedIn and YouTube host case videos; paid search captures high-intent clinician queries; email segments nurture by specialty.
Marketing Automation & ABM
Salesforce/Pardot powers segment-based workflows; CRM-driven ABM targets top IDNs with integrated CLM content for field enablement.
Webinars & Virtual Rounds
Post-2020 expansion yields webinars with 300–800 HCP attendees and 10–15% converting to trials within 90 days.
Traditional Channels
Conference presence at ASA, SAGES, SGNA, ACG; print in specialty journals and outcomes posters support formulary and purchasing wins.
Data-Driven Personalization & Pilots
Dynamic content by role, ROI calculators, and propensity-model pilots drove a roughly 20% improvement in SDR productivity during 2023–2024; spend shifted toward GI and pain after divestiture.
- Role-based dynamic content for clinicians, materials management, and value analysis
- ROI calculators modeling reductions in malpositioned feeding tubes and opioid use
- Propensity modeling prioritized accounts with ASC pain volume growth signals
- Influencer strategy centers on clinician KOLs for credibility and compliance
Avanos PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Is Avanos Positioned in the Market?
Avanos positions as a focused medtech innovator delivering clinically superior, evidence-backed solutions that reduce complications and total cost of care, emphasizing patient safety, procedure efficiency, and opioid-sparing pain management aligned with hospital value metrics.
Core positioning
Focused specialty depth in enteral access and interventional pain; messaging ties directly to reduced complications and measurable cost savings.
Clinical credibility
Evidence-backed claims supported by guideline citations and awards for enteral feeding and RF techniques enhance trust among clinicians and purchasers.
Visual and tonal identity
Clean, clinical visuals and an authoritative, practical tone foreground data, guidelines, and workflow fit across touchpoints.
Customer promise
Reliable supply, robust clinical support, and measurable improvements in patient outcomes and staff efficiency are core experience commitments.
Brand consistency and adaptive messaging maintain relevance across market shifts, budget tightening, and care-site migration to ASCs while supporting Avanos sales strategy and Avanos marketing strategy.
Differentiation
Specialty depth over breadth with strong recognition in enteral access/placement and interventional pain; use of head-to-head evidence and training to defend share.
Health-economics focus
When budgets tighten, messaging shifts to health-economic data showing reduced length-of-stay and lower total cost of care to meet value analysis needs.
Go-to-market adaptability
Pivot toward ASC efficiency and outpatient workflow fit as care shifts; integrates Avanos go-to-market approach with targeted hospital and ASC segmentation.
Touchpoint consistency
Coordinated website, congress booths, IFUs, and sales materials ensure cohesive Avanos product positioning and branding and messaging strategy.
Competitive responses
Emphasizes head-to-head clinical evidence, training support, and conversion programs to de-risk changeover and aid Avanos customer acquisition strategy for hospitals.
Performance metrics
Marketing and sales measure success via reduction in complication rates, procedure time, opioid consumption, and average case-cost—data often used in value dossiers.
Execution levers
Strategic elements in Avanos sales strategy for medical devices and Avanos marketing strategy for healthcare products focus on evidence, economics, and workflow.
- Deploy peer-reviewed data and guideline citations to support claims
- Offer training and conversion incentives to reduce adoption friction
- Use health-economic models to address hospital value-analysis committees
- Segment messaging by hospital, ASC, and clinic to improve targeting
For further organizational context see Mission, Vision & Core Values of Avanos which complements understanding of Avanos company strategy and Avanos go-to-market strategy for wound care and other specialties.
Avanos Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Are Avanos’s Most Notable Campaigns?
Key Campaigns highlight targeted, evidence-driven programs that supported Avanos company strategy across GI/enteral, interventional pain, portfolio rationalization, and clinical education from 2021–2025, driving conversions, MQL flow, and account revenue lift.
Enteral Safety & Placement Accuracy (2022–2024)
Objective: drive conversions to Cortrak/Corflo systems by quantifying reductions in malposition and radiography; Creative: 'See the Right Path' using real-world placement visualization; Channels: SCCM, ASPEN symposia, KOL webinars, outcomes calculators, LinkedIn video case studies; Results: double-digit GI/enteral growth and select IDN conversions yielding 10–20% account revenue lift with fewer confirmatory X‑rays.
Opioid‑Sparing Interventional Pain (2021–2024)
Objective: position RF ablation and nerve block solutions as opioid alternatives for chronic knee and spine pain; Creative: 'Treat Pain at the Source' with clinical narratives and cost-offset models; Channels: ASA and NANS booths/workshops, peer content, SEO/SEM on procedure terms; Results: increased ASC adoption, webinars converting 10–15% of attendees to trials within 90 days and pipeline growth where ASC pain volumes rose high single digits.
Portfolio Focus & Respiratory Divestiture (2024)
Objective: maintain customer confidence after sale of Respiratory Health (~$110M) and clarify focus on GI and pain; Creative: stakeholder letters, FAQs, rep briefings stressing supply continuity; Channels: direct outreach, website hub, distributor coordination; Results: limited churn in non-core SKUs and redeployment of marketing spend to higher‑ROI franchises.
Clinical Education Series & CME Expansion (2023–2025)
Objective: build clinician preference through evidence and training; Creative: modular video labs, case libraries, CME courses; Channels: YouTube, learning portals, email nurture, society partnerships; Results: sustained MQL flow, ~20% SDR productivity uplift via propensity-based targeting and strengthened clinician-first brand positioning.
These campaigns reflect Avanos sales strategy and Avanos marketing strategy by aligning product positioning, customer segmentation, and go-to-market tactics to measurable outcomes; more context on strategic evolution is available in Growth Strategy of Avanos.
Channels & Activation
Conference symposia, KOL webinars, SEO/SEM, social video, and rep-led briefings were primary activation vehicles to reach hospital procurement, IDNs, and ASCs.
Measurement & Outcomes
Key metrics tracked: conversion-to-trial rates, account revenue lift, confirmatory imaging reductions, MQL-to-opportunity velocity, and SDR productivity.
Value Messaging
Messaging emphasized clinical outcomes, cost offsets, and operational efficiencies to support value analysis and procurement approvals.
Customer Segmentation
Targets included IDNs, ASCs, critical care teams, and gastroenterology services using tailored content and outcomes calculators for each segment.
Commercial Impact
Campaigns supported cleaner portfolio positioning post-divestiture and redeployed budget to GI and pain franchises with higher ROI per dollar spent.
Digital Tools
Outcomes calculators, video case studies, and CME portals improved digital engagement and contributed to measurable trial conversion lift.
Avanos Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Avanos Company?
- What is Competitive Landscape of Avanos Company?
- What is Growth Strategy and Future Prospects of Avanos Company?
- How Does Avanos Company Work?
- What are Mission Vision & Core Values of Avanos Company?
- Who Owns Avanos Company?
- What is Customer Demographics and Target Market of Avanos Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.